No Data
BTIG Maintains Cerus(CERS.US) With Hold Rating
TD Cowen Maintains Cerus(CERS.US) With Buy Rating, Maintains Target Price $5
Craig-Hallum Maintains Cerus(CERS.US) With Buy Rating, Announces Target Price $5
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX)
BTIG Sticks to Its Hold Rating for Cerus (CERS)
Cerus Corporation (NASDAQ:CERS) Just Reported, And Analysts Assigned A US$4.25 Price Target